posted
These guys have no chance at crashing in my opinion. They are a couple of bucks, but if you take a look at the chart and this PR I think you might agree that they are destined to be one of these 40-50 dollar stocks in the long run. Any opinions welcome.
2004-01-20 09:35:35
Sinovac Biotech Ltd. is First Company in the World to Gain Approval to Conduct Clinical Trials on SARS Vaccine
***
Health/Medical Writers / Business Editors BEIJING--(BUSINESS WIRE)--SNVBF-- Sinovac Biotech Ltd. ("Sinovac") (OTCBB:SNVBF) is pleased to announce that it has been approved to commence clinical trials of a vaccine for SARS by SFDA (Chinese FDA). Animal tests on safety, efficacy and immunogenicity have been completed successfully. Immune response was invoked by the vaccine in all animal models. No immune enhancement was observed in any of the pre-clinical testing. Clinical protocols have been developed with the cooperation of the World Health Organization, Chinese FDA, China CDC and the China Medical Academic College. Phase I human clinical trials, testing for safety, are expected to start soon on 30 volunteers. The ultimate aim of the vaccine will be to provoke the body's immune system into action, so that it can destroy the SARS virus if infected. For further information please refer to the Company's filings with the SEC on EDGAR, or refer to Sinovac's website at www.sinovac.com. MANAGEMENT OF SINOVAC WHO TAKE FULL RESPONSIBILITY FOR ITS CONTENTS HAS PREPARED THIS NEWS RELEASE. THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC'S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. THIS NEWS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION. KEYWORD: INTERNATIONAL ASIA PACIFIC INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Sinovac Biotech Ltd CONTACT INFORMATION: Sinovac Biotech Ltd Graham Taylor, 888-888 8312 or 604-684-5990 Email: info@sinovac.com Website: www.sinovac.com
posted
These are my kind of drug dealers baby! lol I'm ridin' this one as far as it will go. My apologies to those that don't like to see something above $0.10 in this forum... I just couldn't let this one slide by everyone.
IP: Logged |
posted
Another tid bit: This 6-K/A was filed by SINOVAC BIOTECH LTD yesterday around 3:00pm eastern... The following is an excerpt that I found interesting.
Item 1. Recent Developments - Changes in Control of Registrant. --------------------------------------------------------------- On September 24, 2003, Mr. Wei Dong Yin entered into a share purchase agreement with Geneva Overseas Holdings Ltd. whereby Mr. Yin acquired 6,544,830 shares from Geneva Overseas Holdings Ltd. at $0.03 per share for a total of $195,000. On September 24, 2003, the Board of Directors of Net Force Systems Inc. appointed Mr. Wei Dong Yin, Ms. Lily Wang, and Mr. He Ping Wang to fill vacancies on the Board. Mr. Yin is President, Chief Executive Officer and Ms. Wang is Chief Financial Officer. Mr. Wei Dong Yin is a director and the General Manager of Sinovac Biotech Co., Ltd. He is responsible for the State Model Project for Hi-tech Industrialization. Mr. Yin has devoted 20 years to the Hepatitis A virus research and is the technological inventor of Inactive Hepatitis A Vaccine. Mr. Yin is also heading the research on Inactivated SARS Vaccine. Mr. Yin is not a director of any other company. Mr. Wang is Vice General Manager with Beijing Fuhua Construction. Mr. Wang commenced employment with Beijing Fuha in 1993. Mr. Wang obtained is Bachelor's Degree from the Beijing Instrument Industrial University. Mr. Wang is not a director of any other company. Ms. Lily Wang is President of USA Xinyu Co. Ltd. Ms. Wang commenced employment with USA Xinyu in 1993. Ms. Wang completed the MBA program in 1993 at The School of Business Administration of USA- University of Hawaii. Ms. Wang is not a director of any other company. On September 24, 2003, Mr. Terry Bowering, Director, President, Chief Executive Officer and Chief Financial Officer, Mr. Trevor Bowering, Director, Mr. Dwight Lewis, Director and Mr. Derek Ferguson, Director, each tendered their resignation to the Board and the Board of Directors accepted each resignation. Upon the Board's acceptance of Mr. Terry Bowering's resignation, Mr. Yin was appointed President and Chief Executive Officer and Ms. Lily Wang was appointed Chief Financial Officer. On September 24, 2003, the Net Force Systems Inc., ("Net Force") a corporation organized under the laws of Antigua and Barbuda and Lily Wang, ("Wang") a natural person of the United States entered into a share purchase agreement together with schedules and exhibits. 2 Ms. Lily Wang owns approximately 51% ownership interest in Sinovac Biotech Co., Ltd. ("Sinovac") a company organized under the laws of the People's Republic of China. Wang desired to sell her Sinovac shares and Net Force desired to acquire her Sinovac shares. Upon completion of this transaction, Net Force gained controlling indirect ownership interest in Sinovac for the consideration of 10,000,000 newly-issued shares of common stock of Net Force, at a stated value of $0.60 per share for a total of $6,000,000 constituting approximately 37% of Net Force's outstanding capital stock after such issuance on a fully-diluted basis. Net Force's Board of Directors approved this transaction and it was executed on September 24, 2003. A copy of the Stock Purchase Agreement has previously been filed. Item 2. Recent Developments - Acquisition of Business. ------------------------------------------------------ Pursuant to the Stock Purchase Agreement, Net Force will acquire from the Sinovac shareholders approximately 51% of the issued and outstanding capital stock of Sinovac. In so doing, Net Force acquired a controlling indirect ownership interest in Sinovac. Sinovac specializes in the research and development of commercialization of human vaccines for infectious illnesses such as Hepatitis A, Hepatitis A&B, influenza and "SARS". This acquisition is essential to the future growth of the Net Force and will fit into the overall strategy of Net Force to expand into the biotechnology industry. In completing this transaction, the company is taking the first step of this strategic shift into this industry. Net Force intends to leverage off such an important base and further expand in the biomedical and biotechnology industries. The acquisition will be treated for accounting purposes as a purchase and is a tax-free exchange under the United States Internal Revenue Code of 1986, as amended. About Sinovac Biotech Co., Ltd. ------------------------------- In 2002, Sinovac Biotech Co., Ltd., successfully launched its Hepatitis A vaccine - the first of its kind developed by Chinese scientists using their proprietary technology with its primary market in China. Sinovac is also currently working towards the near-term launch of a combined Hepatitis A&B vaccine for domestic and foreign markets. Clinical trials for this proprietary biomedical innovation have recently been completed and are currently been evaluated. To date only one combined vaccine (Twinrix) has been developed by multinational pharmaceutical giant Glaxo Smith Kline. Sinovac will compete in this market with Glaxo Smith Kline. Sinovac's proprietary, cost-effective vaccines are expected to keep the company at the forefront of China's emerging biopharmaceutical industry and to offer developing Southeast Asian nations with low-cost alternatives to the more expensive vaccines offered today. A survey conducted by Glaxo Smith Kline suggests that China's market for the Hepatitis A vaccine will be worth approximately US$1.5 billion by 2005. While expanding the domestic market for vaccines, Sinovac and Sino Pharma are committed to aggressively targeting overseas markets for such in-development vaccines as the combined Hepatitis A&B and the awaited SAR biotechnologies. A joint venture marketing agreement has already been signed with Best Invent Technology - a subsidiary of Indonesia's leading pharmaceutical company, P Kalbe Farma tbk. Item 3. Other Events and Regulation FD Disclosure ------------------------------------------------- This current report contains forward-looking statements regarding future events and future performance of the Company, including statements with respect to consummation of a proposed transaction and commercialization of products, all of which involve risks and uncertainties that could materially affect actual results. Such statements are based on Management's current expectations and actual results could differ materially. Investors should refer to documents that the Company files from time to time with the Securities and Exchange Commission for a description of certain factors that could cause the actual results to vary from current expectations and the forward-looking statements contained in this report. Such Filing includes, without limitation, the Company's Form 20F and Form 6-K reports.
posted
I was in a while back at something like $1.90. I sold out because things were slowing down at $2.40 something. I would have stayed in but I needed the dough for a faster mover that week. I have the $$ to play with now and I'm in again. This time at 2.75 believe it or not. I'm sure it could retrace just a bit due to the MACD and RSI but I personally don't care. That will be when I buy in for more shares. These guys are gold either way as far as I can see. I just got done e-mailing the company with a short list of questions. Should get a reply back by Monday I would think. Something to look forward to I'd say.
IP: Logged |
posted
I personally think that you already saw the retrace. I could be completely wrong though. I think it's seen its low for the week and probably for next week as well. Just an opinion. Time will tell.
IP: Logged |
posted
Oops sorry about the previous blank reply. With regards to the nature article: I do agree that the Sinovac Vaccine looks promising, but keep in mind that using a whole dead strain of virus to elicit an immune response is somewhat antiquated. This may not yield as potent and directed a response as the potential therapy designed by Gambotto's team. Since Gambotto's team is directing an immune response against a modified/attenuated strain of SARS, my money would be on them. This is similar to the Salk/Sabin polio vaccine efficacies...(attenuated vs. heat inactivated..). Time will tell. And then again, it's not the cure that matters right? Only that people have faith in it and the stock rises..hehe
IP: Logged |
JOHNDAVID brought us the link to Nature--I was pleased to see a non-financial reference here.Not that scientist don't pump as much as financials--- and the scientific analysis is appreciated.
Note the 51% insider hold ---
[
[This message has been edited by glassman (edited January 30, 2004).]
posted
Antiquated or not; Edward Jenner's methods were obscene they were so antiquated... scratching the arms of people not yet infected with Smallpox and rubbing the fluid from a pock of someone who had cowpox! That's one step above bleeding the sickness out of someone it would seem. But it worked and saved half of the world. I narrowly avoided getting vaccinated for Smallpox in September last year (being in the USAF at that time). They are still basically doing the same thing today as Jenner did. Given its more sanitary by leaps and bounds, but its the same thing. My point is that every virus is different. Some like smallpox have what could be considered a close relative like cowpox. In its case, those infected with cowpox are immune to smallpox... This being the first vaccine, the word "vaccine" was assigned to this kind of treatment... "Vacca" meaning Cow. They were treating viruses with completely different viruses. As far as dealing with dead or live stains its kind of a moot point. Viruses do not possess all of the characteristics of life. They are according to Biology, "not living". Some are more complicated that others but in brief, all a virus is, is a little rouge section of DNA floating around in a sack. The sack hits you, and a natural reation occurs with your cells due to the random genetic code of whatever virus it is, causing you to get sick and even die. I believe these guys are on the right track and I'm sure that they are not only persuing one method of research at a time. After all the Chinese Government is on these guys back. And assuming that world pressure outweighs their government's desire for population control, we should be seeing results ASAP. Here are a few links concerning my comments. http://www.jennermuseum.com/http://www.google.com/search?hl=en&ie=UTF-8&oe=UTF-8&q=Edward+Jennerhttp://www.uq.edu.au/vdu/KidsVirusesAlive.htmhttp://www.google.com/search?hl=en&lr=&ie=UTF-8&oe=UTF-8&q=virus+not+alive
Don't mean to seem like I'm lashing out or anything, and I'm certainly not challanging anyone's intellect. All I say is that if you figure out a way to fix a broken vase with a hammer then do it! That's what Jenner did. I pray these guys will too.
quote:Originally posted by glassman: You sound like my better half......
JOHNDAVID brought us the link to Nature--I was pleased to see a non-financial reference here.Not that scientist don't pump as much as financials--- and the scientific analysis is appreciated.
Note the 51% insider hold ---
[
[This message has been edited by glassman (edited January 30, 2004).]
i don't think the scientific community EVER agrees on anything anyway-- that's why we keep discovering new things--
SARS-- My take on it in specific is that the big players in world health blew it all out of proportion anyway-- not that it isn't scary but the fact that it is scary was an oppurtuniity to hype and practice a new form of anti-terrorrism--get lots pof players to stop bickering and work together--get more money-- the numbers of people dying did not support the reaction--- this comes from SCIENCE-- i don't read every article or even half so i could have missed something- but--it could have been a real epidemic and i didn't see us stopping it with science--it died out on its own and it could /should come back because the civets are still being eaten in asia. WW1 was not ended by the US doughboys--it was ended by the FLU--we need to get a vaccine system going like this whichever way we go.
Can you post in English next time. I am just kidding my friend. That is a conversation way over my simple head. LOL. JD, Thanks for bringing this company to our attention. It looks very promising. Now just to find some cashola to throw in it. I am going to go find some, bye. Mac
posted
Hmm, virii. An interesting topic albeit a bit off topic, but not really.
True, in the scientific world virii are not considered alive having failed the usual test for intake of energy, this is, eating.
However, virii do eat, just not very often!
Many virii encapsulate and survive for millions of years, without usual signs of life. Yet they live, they do emerge, and they do take us by unpleasant surprise.
Inherent problem and benefit of virii is natural mutation. This is a problem because we cannot keep up. This is a benefit because of population control.
A cure for SARS. Possibly, but I am skeptical knowing a new SARS virus form will appear.
If humankind could cure viral infections, we wouldn't be beseiged with commercials for herpes control, yes?
Seems a bit late for a SARS "cure" but this does not mean money is not to be made. This money to be made is based on a fear of a viral disease which may no longer exist in the form, of which we know today.
posted
One of the reasons I frequently become concerned when I see anthropologists on Nat Geo and Discovery channel opening tombs and examining mummies without taking proper sterile precautions. How do they know why this person passed?
IP: Logged |
posted
Glassman made a great point when he mentioned SARS being blown out of preportion. I was I southern ontario for 8 months during high point of the SARS "outbreak". I can tell you, besides limited acess to hospitals and airports covered with health advisories, it was not that big of a deal. SARS only really effected the very weak (old or infant) and was very isolated. Needless to say, the media got a hold of it and had a field day. We are in the resort business and 99% of our guests are American. They did not start voicing concerns over SARS untill they "outbreak" was basically over in Canada, however the U.S media was just beginning to play the SARS card.
However, I do agree it is some-what of a threat. Regarless of how dangerous it is, all that really matters to profit in a huge way from SARS is hype. If people are willing to over-react (its clear they are) then a vacine would be huge.
posted
Hey Shushan; Wasn't aiming for you to not reply or whatever. Seriously didn't mean to sound hostile at all. Never had yelling in mind while I was typing Promise! Wasn't even upset actually.
At least post a reply again to tell me to work on my people skills.
I'm interested in what field of study you're in as well.
posted
PLEASE note--shushan--i have read lots of his posts-he's not bashing you --i often write quickly and post thngs that are not clearly polite without realizing it too--especially cuz i'm a lazy typer-LOL
also--SARS was/is important in sense of developing fast-reaction strategy for ANY viral epidemic in modern age using new "molecular" techniques--teamwork in this community has been abyssmal
in my opinion-- molecular marking /ID/trasngenesis/RNAI/promoter manipulation techniques are the REAL DEAL and the next true dotcom type of investment opportunity--i don't like to compare to dotcom cuz of bubble burst but the bubbles almost always happen anyway--the good news is that it is hard to believe some of the advances even by peers-- this will slow down the craziness of the dotcom-but anybody who follows these fields knows that the future is VERY BRIGHT-----I like SQNM here for starters they are still a good buy IMO.
[This message has been edited by glassman (edited February 01, 2004).]
A relative died from this disease. This is a viral infection very commonly associated with ancient American Indian burial sites, very much a "curse" for disturbing those sacred burial grounds.
Being of American Indian descent, this is of great interest to me, perked by a sad death of a relative.
Asians are very susceptable to this disease. As you know, American Indians are direct descendants of those who migrated across the Bering Straight from the Asian areas, tens of thousands of years back. I have no doubt, they brought Valley Fever with them, to the Americas.
Little or no incident of this in colder climates, such as Alaska. It is specific to dry dusty wind blown regions.
SNVBF, does sound interesting. I will be taking a look at this stock.
posted
Check it out everyone... More good news. You just can't lose with this one right now! An ACQUISITION... That's right a complete acquisition of Tangshan Yian Biological Engineering Co., Ltd.
Sinovac Biotech Ltd. Announces Completion of the Acquisition of Tangshan Yian Biological Engineering Co., Ltd. E-mail or Print this story
30 January 2004, 5:11pm ET
BEIJING, CHINA--Sinovac Biotech Ltd. ("Sinovac") (NASD OTC-BB: SNVBF) is pleased to announce that on January 26, 2004, Sinovac executed the formal share purchase agreement (the "Share Purchase Agreement") between Sinovac, Tangshan Yian Biological Engineering Co., Ltd. ("Tangshan Yian"), a company organized under the laws of the People's Republic of China, and Mr. He Ping Wang, the sole shareholder of Tangshan Yian and also a director of Sinovac. The Share Purchase Agreement provides that Sinovac will acquire 100% of the issued and outstanding shares of Tangshan Yian in exchange for issuing 3,500,000 shares of common stock of Sinovac plus US$2,200,000 in cash, which will be payable by Sinovac within 12 months from the date of entering into the Share Purchase Agreement, to Mr. He Ping Wang. As of January 30, 2004, all of the terms and conditions of the Share Purchase Agreement have been satisfied and the acquisition of Tangshan Yian by Sinovac is now completed.
Tangshan Yian operates in the city of Tangshan, People's Republic of China, as a research and development company specializing in the development and manufacturing of various vaccines including flu, and vaccines for Hepatitis A and Hepatitis A&B. Tangshan Yian supplies these vaccines to Sinovac's subsidiary, Sinovac Biotech Co., Ltd. The research and development operations of Tangshan Yian are expected to supply increased quantities of new and updated vaccines to the domestic Chinese and international markets.
For further information please refer to the Company's filings with the SEC on EDGAR or refer to Sinovac's website at http://www.sinovac.com/.
MANAGEMENT OF SINOVAC WHO TAKE FULL RESPONSIBILITY FOR ITS CONTENTS HAS PREPARED THIS NEWS RELEASE. THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC'S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. THIS NEWS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
FOR FURTHER INFORMATION PLEASE CONTACT: Sinovac Biotech Ltd. Graham Taylor (888) 888 8312 or (604) 684-5990 Website: www.sinovac.com/